BACKGROUND
There is no cure for Nonobstructive Hypertrophic Cardiomyopathy (nHCM). Adult patients with nHCM often experience heart failure, which is resistant to beta blockers and calcium channel blockers. A top pharmaceutical company launched a global clinical trial to address this critical unmet need.
CHALLENGE
Several studies indicate that awareness changes the attitudes of patients toward clinical trials participation. In one study, 85% of patients were either unaware or unsure that participation in a clinical trial was an option for them and 75% of these patients said they would have been willing to enroll had they known it was possible. This top pharma client asked Jumo Health to develop an engaging and culturally relevant recruitment campaign that would appeal to a diverse global audience for this large phase II study.
STRATEGY
Jumo Health developed a comprehensive curriculum of digital and print resources that resonated with each unique community the study was trying to reach. Study resources incorporated regionally localized imagery allowing participants to identify with the materials. The curriculum was translated into 10 languages so that patients could be reached on a global scale. This tailored educational approach improved both recruitment and retention efforts for the study.
47%
Increase in Enrollment
25%
Screen Fail Improvement
100%